Genetic lesions in diffuse large B-cell lymphomas.

Journal Article (Journal Article;Review)

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35%-40% of all cases. The combination of the anti-CD20 monoclonal antibody rituximab with anthracycline-based combination chemotherapy (R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) lead to complete remission in most and can cure more than half of patients with DLBCL. The diversity in clinical presentation, as well as the pathologic and biologic heterogeneity, suggests that DLBCL comprises several disease entities that might ultimately benefit from different therapeutic approaches. In this review, we summarize the current literature focusing on the genetic lesions identified in DLBCL.

Full Text

Duke Authors

Cited Authors

  • Testoni, M; Zucca, E; Young, KH; Bertoni, F

Published Date

  • June 2015

Published In

Volume / Issue

  • 26 / 6

Start / End Page

  • 1069 - 1080

PubMed ID

  • 25605746

Pubmed Central ID

  • PMC4542576

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdv019


  • eng

Conference Location

  • England